专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO1996013710A1 LASER IMAGING SYSTEM USING SELF-DETECTION FOR CONFOCALITY 审中-公开
标题翻译：激光成像系统使用自检来进行协调
公开(公告)号：WO1996013710A1
公开(公告)日：1996-05-09
申请号：PCT/US1995011826
申请日：1995-09-18
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
发明人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC. , WEBB, Robert, H. , ROGOMENTICH, Fran, J.
IPC分类号： G01N21/55
CPC分类号： G01S17/89 , G01S7/4815 , G01S7/4916 , G02B21/0032 , G02B21/004
摘要： The invention relates to a confocal laser imaging system and method. The system includes a laser source (10), a beam splitter (S), focusing elements (L) and (L'), and a photosensitive detector (20). The laser source (10) projects a beam along a first optical path at an object (OB(0)) to be imaged, and modulates the intensity of the projected laser beam in response to light reflected from the object (OB(0)). A beam splitter (S) directs a portion of the projected laser beam onto a photodetector (20). The photodetector (20) monitors the intensity of laser (10) output. The laser source (10) can be an electrically scannable array, with a lens (L) or objective assembly for focusing light generated by the array onto the object of interest (OB(0)). As the array is energized, its laser beams scan over the object (OB(0)), and light reflected at each point is returned by the lens (L) to the element of the array from which it originated. A single photosensitive detector element (20) can generate an intensity-representative signal for all lasers of the array. The intensity-representative signal from the photosensitive detector (20) can be processed to provide an image of the object (OB(0)) of interest.
摘要翻译：本发明涉及一种共焦激光成像系统及方法。该系统包括激光源（10），分束器（S），聚焦元件（L）和（L'）以及光敏检测器（20）。激光源（10）沿着要被成像的物体（OB（0））的第一光路投射光束，并且响应于从物体（OB（0））反射的光调制投射的激光束的强度，。分束器（S）将投射的激光束的一部分引导到光电检测器（20）上。光电检测器（20）监视激光（10）输出的强度。激光源（10）可以是电可扫描阵列，具有用于将由阵列产生的光聚焦到感兴趣对象（OB（0））上的透镜（L）或物镜组件。当阵列通电时，其激光束在物体（OB（0））上扫描，并且在每个点处反射的光被透镜（L）返回到从其发射的阵列的元件。单个光敏检测器元件（20）可以为阵列的所有激光器产生强度代表信号。可以处理来自光敏检测器（20）的强度代表信号以提供感兴趣的对象（OB（0））的图像。

22. 发明申请

WO1993020439A1 COMPOSITIONS AND METHODS FOR REGULATING CELLULAR SIGNAL TRANSDUCING SYSTEMS 审中-公开
标题翻译：用于调节细胞信号转导系统的组合物和方法
公开(公告)号：WO1993020439A1
公开(公告)日：1993-10-14
申请号：PCT/US1992002632
申请日：1992-03-30
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE
发明人： THE SCHEPENS EYE RESEARCH INSTITUTE , SCHMIDT, Geoffrey, J.
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , A61K38/00 , A61K47/62 , C07K14/4722 , C07K16/18 , G01N33/57484 , G01N33/6872
摘要： Disclosed is a method of regulating the metabolic pathway of inositol in a cell. This method includes the introduction into said cell of a molecule which is then allowed to couple a membrane-bound receptor, activatable by an external signal, to an intracellular phosphodiesterase of the type responsible for generating second messenger substance, IP3. This molecule is selected from the group consisting of a purified A-protein, and active fragments, active analogs, and active fusion products thereof. Also disclosed are methods of detecting an A-protein and methods of inhibiting the growth and proliferation of cancer cells using anti-A-protein antibodies.
摘要翻译：公开了调节细胞中肌醇的代谢途径的方法。该方法包括将所述细胞引入所述细胞，然后允许其将由外部信号激活的膜结合受体偶联至负责产生第二信使物质IP3的类型的细胞内磷酸二酯酶。该分子选自纯化的A蛋白和活性片段，活性类似物及其活性融合产物。还公开了检测A蛋白的方法和使用抗A蛋白抗体抑制癌细胞的生长和增殖的方法。

23. 发明申请

WO2021222476A2 HIGH EFFICIENCY GENE DELIVERY SYSTEM 审中-公开
公开(公告)号：WO2021222476A2
公开(公告)日：2021-11-04
申请号：PCT/US2021/029757
申请日：2021-04-28
申请人： PRESIDENT AND FELLOWS OF HARVARD COLLEGE , MASSACHUSETTS EYE AND EAR INFIRMARY , THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
发明人： FLOREA, Michael , WAGERS, Amy, J. , VANDENBERGHE, Luk
IPC分类号： A61K35/76 , A61K35/761 , A61K38/18 , A61K38/45 , A61K48/00 , A01K2217/075 , A01K2227/105 , A01K2267/035 , A61K48/005 , C12N15/86 , C12N2750/14143
摘要： The disclosure provides viral vector delivery systems for use in treating diseases or disorders in a subject to whom the viral vector delivery systems are administered, as well as to methods of making and using the viral vector delivery systems.

24. 发明申请

WO2021113515A1 INJECTABLE HYDROGELS FOR CELL DELIVERY TO THE VITREOUS 审中-公开
公开(公告)号：WO2021113515A1
公开(公告)日：2021-06-10
申请号：PCT/US2020/063115
申请日：2020-12-03
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC. , MASSACHUSETTS INSTITUTE OF TECHNOLOGY , THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
发明人： COLOMBE, Pierre A. , SINGH, Deepti , SPECTOR, Myron , YOUNG, Michael
IPC分类号： A61K47/48 , C08G73/02 , C08L79/02
摘要： The present disclosure presents hydrogel compositions for use in the treatment of an ocular disorder (e.g., a retinal disease) and methods of treating an ocular disorder in a subject in need thereof with the hydrogel compositions. The hydrogel compositions can include hydroxyphenylpropionic acid (gelatin-HPA), hyaluronic acid-tyramine (HA-Tyr), a catalyzer (e.g., horseradish peroxidase (HRP)), a cell, a crosslinker (e.g., hydrogen peroxide), or any combination thereof. The methods include administering a therapeutically effective amount of a composition into an eye of the subject, wherein the composition includes any of the hydrogel compositions of the disclosure.

25. 发明申请

WO2020243496A1 A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS 审中-公开
公开(公告)号：WO2020243496A1
公开(公告)日：2020-12-03
申请号：PCT/US2020/035222
申请日：2020-05-29
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
发明人： DANA, Reza , CHEN, Yihe
IPC分类号： C07D401/00 , C07D401/04 , C07D413/00
摘要： Disclosed are methods of treating a non-infectious ocular immunoinflammatory disorder in a subject. Methods of reducing a symptom, e.g., ocular redness, of a non-infectious ocular immunoinflammatory disorder in a subject, and pharmaceutical composition containing an SP blocker, an SP antagonist, an SP receptor blocker or an SP receptor antagonist as an active component and a pharmaceutically acceptable carrier or excipient are also described.

26. 发明申请

WO2020190848A1 ISOLATION, ENRICHMENT AND EXPANSION OF CONE PROGENITOR CELLS AND USES THEREOF 审中-公开
公开(公告)号：WO2020190848A1
公开(公告)日：2020-09-24
申请号：PCT/US2020/022929
申请日：2020-03-16
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC. , MASSACHUSETTS EYE AND EAR INFIRMARY , MASSACHUSETTS INSTITUTE OF TECHNOLOGY
发明人： YOUNG, Michael, J. , COLOMBE, Pierre , SINGH, Deepti
IPC分类号： A61K35/12 , A61K35/28 , A61P27/02
摘要： Progenitor cells were isolated, purified and expanded using a microfluidic based cell sorting approach. The methods were successfully in purifying cone progenitor cells (CPCs) defined based on a proliferative population expressing cone arrestin and Red/Green (R/G) opsin at greater than 80% using a two multistage approach.

27. 发明申请

WO2019178100A1 PREDICTING RESULT REVERSALS OF GLAUCOMA HEMIFIELD TESTS 审中-公开
公开(公告)号：WO2019178100A1
公开(公告)日：2019-09-19
申请号：PCT/US2019/021852
申请日：2019-03-12
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
发明人： WANG, Mengyu , SHEN, Lucy Q. , PASQUALE, Louis R. , ELZE, Tobias
IPC分类号： A61B3/00 , A61B3/10 , A61B5/00
摘要： Methods, systems, and devices are provided for determining and/or predicting result reversals and/or false positive results of the glaucoma hemifield test, for example by assessing VF (visual field) mismatch features and quantifying the VF loss patterns in addition to the VF global indices. In general, if the test results generate consecutive ONL results, groups of features can be extracted from the VF results collected, such as the average VF global indices, VF mismatch measures between baseline VFs, and the archetype decompositions of the mean baseline VFs. The VF results can be decomposed into VF patterns (or archetypes). Reversal of GHT results can then be predicted based on an analysis by one or more processors of the data provided, for example by using logistic regression.

28. 发明申请

WO2019173334A1 ENGINEERED VEGF VARIANTS FOR RETINAL NEUROPROTECTION, PROMOTION OF AXON GROWTH AND AXON REGENERATION 审中-公开
公开(公告)号：WO2019173334A1
公开(公告)日：2019-09-12
申请号：PCT/US2019/020744
申请日：2019-03-05
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
发明人： NG, Yin, Shan Eric , SHEN, Junhui
IPC分类号： A61K38/00 , A61K38/18 , C07K14/475 , C07K19/00 , C12N15/09 , C12N15/62
摘要： The invention represents a solution for major unmet medical need in the field of ophthalmology. Accordingly, the invention provides compositions, e.g., an engineered Vascular endothelial growth factor (VEGF) chimeric polypeptide, comprising a flexible transmembrane anchor such as a chimeric polypeptide comprising a polypeptide linker with a length of 38-53 amino acids, inclusive. Exemplary chimeric polypeptides include e-VEGF38, and eVEGF-53. A retinal ganglion cell (RGC) comprising a membrane anchored VEGF polypeptide is also within the invention.

29. 发明申请

WO2019169172A1 SYSTEM AND METHOD FOR TREATING MEIBOMIAN GLAND DYSFUNCTION 审中-公开
公开(公告)号：WO2019169172A1
公开(公告)日：2019-09-06
申请号：PCT/US2019/020113
申请日：2019-02-28
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE
发明人： SULLIVAN, David, A. , LIU, Yang
IPC分类号： A61F9/00 , A61P27/02
摘要： Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.

30. 发明申请

WO2019169166A1 VISUAL FIELD PROGRESSION 审中-公开
公开(公告)号：WO2019169166A1
公开(公告)日：2019-09-06
申请号：PCT/US2019/020106
申请日：2019-02-28
申请人： THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
发明人： WANG, Mengyu , SHEN, Lucy, Q. , PASQUALE, Louis, R. , ELZE, Tobias
IPC分类号： A61B3/00 , A61B3/024
摘要： Methods, systems, and devices are provided for determining visual field progression of a patient. An exemplary method can include decomposing a present visual field and a plurality of past visual fields of the patient into a plurality of weighted visual field archetypes; determining whether each of the plurality of weighted visual field archetypes is increasing or decreasing in size relative to itself across the plurality of past visual fields and the present visual field; and determining if the patient is experiencing a loss of visual field based on the determination of whether each of the plurality of weighted visual field archetypes is increasing or decreasing.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式